Heartbeam Inc
NASDAQ:BEAT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (21.8), the stock would be worth $-7.93 (999% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -2.4 | $0.88 |
0%
|
| Industry Average | 21.8 | $-7.93 |
-999%
|
| Country Average | 21.9 | $-7.95 |
-1 002%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Heartbeam Inc
NASDAQ:BEAT
|
35.4m USD | -2.4 | -1.7 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
162.6B USD | 65.3 | 56.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
155.4B USD | 29 | 24.8 | |
| US |
|
Stryker Corp
NYSE:SYK
|
112.7B USD | 20.7 | 34.7 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
102.7B USD | 27.3 | 22.3 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
83.8B USD | 29.3 | 23.5 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.8B USD | 37 | 44.5 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.3B EUR | 41.4 | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.2B USD | 46 | 42.7 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.5B USD | 17.6 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
29.9B USD | 17.2 | 20.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.1 |
| Median | 21.9 |
| 70th Percentile | 36.5 |
| Max | 3 188 432.5 |
Other Multiples
Heartbeam Inc
Glance View
HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. The company is headquartered in Santa Clara, California and currently employs 5 full-time employees. The company went IPO on 2021-10-14. The company specializes in cardiovascular diagnostic technology. The company is primarily focused on telemedicine solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company focuses on providing diagnostic data to help physicians with care management of patients with cardiovascular disease. The company delivers remote diagnostic and monitoring technologies that can be used for patients anywhere for ambulatory and emergency room (ER) use. Its telehealth product is comprised of a credit card-sized Electrocardiogram (ECG) machine and a cloud-based diagnostic software system. The company is applying its platform technology to create a software tool for detecting heart attacks in the ED environment. This software tool is designed to enable emergency physicians to diagnose heart attacks. Its credit card sized cardiac electrical signal collection device captures cardiac signals that represent projections of the heart vector.
